Extended Data Fig. 6: MALT1 promotes the immune-suppressive function of TAMs.
a, Representative FACS analysis plot for CD11b+, F4/80+ macrophages infiltrated in E0771-VEC, E0771-M-WT, and E0771-M-PD tumor samples. b-c, Quantification of the percentages of CD8+ (b) and CD4+ (c) T cell among all living cells from E0771-VEC, E0771-M-WT, and E0771-M-PD tumor samples. n = 5 mice per group. Data represent mean ± SD. d, Quantifications of the percentage of macrophages among CD45+ cells, MFI of MHC-II and CD206 on macrophages, percentage of CD45+CD8+ and CD45+CD4+ T cells among living cells from E0771-CTRL, MALT1-KD1, and -MALT1-KD2 tumor tissues. n = 8 mice per group. Data represent mean ± SD. e, Similar experiments were performed as in (d) for PyMT-A cells. n = 5 mice per group. Data represent mean ± SD. f, Quantification of the survival rates of B16F10-VEC, B16F10-M-WT, and B16F10-M-PD cancer cells in co-culture system with activated CD8+ T cells (- MΦ group) and in tri-culture system ( + MΦ group). The ratio of tumor cells, macrophages and T cells is 1: 4: 4. n = 6 biological independent samples. Data represent mean ± SD. g, FACS analysis of the percentage of macrophage (CD11b+ F4/80+) among CD45+ cells from lungs of mice injected with either PBS (left) or α-CSF1R neutralizing antibody (right). h, FACS analysis of CD8+ T cell (TCRβ+CD8+) percentage among CD45+ cells from spleens of mice injected with PBS (left) or α-CD8 neutralizing antibody (right). For b–f, one-way ANOVA with Dunnett’s multiple comparisons test.
